CLRB — Cellectar Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $90.34m
- $50.31m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 14.2 | 15.1 | 24.1 | 28.8 | 39 |
Operating Profit | -14.2 | -15.1 | -24.1 | -28.8 | -39 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.1 | -15.1 | -24.1 | -28.7 | -38 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.1 | -15.1 | -24.1 | -28.6 | -38 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.1 | -15.1 | -24.1 | -28.6 | -38 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.1 | -15.1 | -24.1 | -28.6 | -38 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -18.4 | -7.71 | -4.35 | -4.05 | -3.11 |